India's Only Dedicated PMO Manufacturer

Advancing
Precision
Medicine

Morpholino oligonucleotide solutions for research & therapeutics

GenElixir® is founded by scientists and healthcare professionals with a three pillar vision: discover next-generation morpholino chemistry, manufacture it at scale, and partner with the world's drug developers.

GenElixir® manufactures and supplies high-purity PMOs, morpholino monomers, and our proprietary self-transfecting GMO-PMO chimera — protected by two US patents. Universities, CDMOs, and drug discovery teams worldwide order from our catalog and ship within days from Visakhapatnam or West Berlin, NJ — at a 40–60% cost advantage over Western peers.

Explore Products →
Stable
Stable
Verified Quality
Non-Toxic
Non-Toxic
Safe Chemistry
Precise
Precise
Confident Results
Cell Permeable
Cell Permeable
Direct Uptake
2
Granted US Patents
+ Gen3/Gen4 Pending
≥95%
HPLC Purity
Certified in-house
40–60%
Cost Advantage
vs US/EU suppliers
5d
India Delivery
Business days
GMO-PMO chimera technology — self-transfecting, US-patent protected
GMO-PMO
Proprietary self-transfecting chimera · US-patent protected

GenElixir at a Glance

What: Manufacturer of Phosphorodiamidate Morpholino Oligonucleotides (PMOs), patented GMO-PMO chimeras, and morpholino monomers.
Where: Headquartered Visakhapatnam, India · USA office West Berlin, NJ.
Founded: 2019 · India's only dedicated PMO manufacturer.
IP: 2 granted US patents (9,914,745 B2 · 12,012,427 B2) + India 523395 + Gen3/Gen4 pending.
Catalog: Robust inventory of monomers (SMMT, SMMF, CMMT, CMMF) and oligomers (PMO, GMO).
Purity: ≥95% HPLC, certified in-house · CoA available.
Cost: 40–60% lower than US/EU competitors (Gene Tools, Hongene, BOC Sciences).
Lead time: 5 business days delivery within India · longer for custom oligomer synthesis.
Differentiator: Patent-protected GMO-PMO chimera — self-transfecting antisense, no delivery reagent required.
Contact: sales@genelixir.com · +91 897 773 4216 (IN) · +1 856 975 0444 (US).
// Brand Essence
Scientific Precise Innovative Clean Trustworthy
Differentiators

Built for the Scientific Community

From university research labs to biotech CDMOs — GenElixir delivers research-grade morpholino chemistry with the precision your science demands and the speed your timelines require.

India's Only Dedicated PMO Manufacturer

The sole manufacturer of PMO monomers and GMO-PMO chimeras in India, giving domestic researchers direct access at significantly lower cost than US or EU alternatives.

Proprietary GMO-PMO Chimera Technology

Our patented self-transfecting GMO-PMO chimeras eliminate the need for viral vectors, electroporation, or lipid transfection reagents — reducing experimental complexity.

40–60% Cost Advantage

Manufacturing in India with a fully in-house synthesis and QC pipeline delivers internationally comparable purity at significantly lower cost than leading global suppliers.

In-House HPLC Verification

Every batch is HPLC-tested in our Visakhapatnam facility. Certificates of analysis confirm ≥95% purity for monomers, ensuring confident synthesis from the first step.

India Delivery in 5 Business Days

Dramatically faster than the 2–4 week lead times from US or China-based suppliers, keeping your research timelines on track and your experiments moving.

Scientific Support & Customization

Our synthetic chemists provide expert guidance on sequence selection, modification chemistry, and experimental design. Custom synthesis to exact specifications.

Product Catalog 2026

Morpholino Oligonucleotide Solutions

Two top-level categories mirroring your workflow: Category MO for research-ready, sequence-specific antisense reagents, and Category MM for in-house PMO synthesis building blocks.

GenElixir Product Catalog 2026 — PDF Download
PDF · Updated June 2026

Download the Full 2026 Product Catalog

Complete product specifications, chemical structures, CAS numbers, molecular formulas, and ordering guidance for all MO oligomers and MM monomers — formatted for offline reference and procurement.

PDF · 722 KB · 6 pages · All 4 monomer sub-families + oligomers with modifications
Download Catalog
MO

Custom Morpholino Oligomers

Custom-synthesized, sequence-specific PMO and GMO-PMO chimera oligomers. R&D grade, milligram scale (Q2 2026); gram scale via industry partnership from 2027.

Custom Sequence 250–500+ nmol 5′ End Mods
PMO

Standard Phosphorodiamidate Morpholino Oligomers

PMOs of 20–30 nucleotides bind target mRNA with high sequence specificity via Watson-Crick base pairing. The non-ionic phosphorodiamidate backbone confers nuclease stability and minimal off-target effects. Four FDA-approved drugs — eteplirsen, golodirsen, viltolarsen, casimersen — are PMO-based.

Unmodified PMO Oligos
PMO · GILPMO301-T

Custom Specified PMO (Antisense)

Sequence-specific PMO tailored to target mRNA. HPLC-purified and QC-tested. For gene silencing, steric blocking, and splice correction research.
Purity ≥85% std · ≥95% HPLC
Appearance White · Lyophilised
Storage −20°C / 2yr
Min. Order 250 nmol
Example Sequence
5′-GGATAAAGACAGCAAATATCCTCAT-3′
PMO · GILPMO301-C

Control PMO (Scrambled / Negative Control)

Scrambled-sequence PMO with no known mRNA target. Paired with antisense PMO to differentiate specific from non-specific effects.
Purity ≥85% std · ≥95% HPLC
Appearance White · Lyophilised
Storage −20°C / 2yr
Example Scrambled Control
5′-AAATTAGGACACCAAATATTCTCAA-3′
5′-End Modifications of PMO

Functional chemistry handles at the 5′ terminus for attachment of fluorescent labels, drugs, peptides, or PEG spacers via Click, Michael addition, or amide coupling reactions.

Catalog No.ModificationChemistryApplication
GILPMO3025′-Alkyne-SerineClick · CuAAC / SPAACBioconjugation with azide-bearing payloads (dyes, PEG, targeting ligands, solid surfaces)
GILPMO3035′-TEG-CysteineThiol-MaleimideMichael addition via TEG spacer. Improved aqueous solubility. SCPh₃-protected thiol.
GILPMO3045′-DEG-CysteineThiol-MaleimideCompact DEG spacer variant. Preferred when close payload proximity is required.
GILPMO3055′-Triethylene Glycol (TEG)Neutral SpacerNon-reactive PEG-like tail. Improves solubility and PK profile. Suited to in vivo / zebrafish studies.

PMO Oligomers — Request a Quote

Standard 250 / 400 / 500 nmol · multiples of 200 nmol above 500 · 5′ modifications available · gram-scale from 2027

Contact for Quote
Length & quantity dependent
↓ Continue to GMO-PMO Chimeras ↓
GMO

GMO-PMO Chimera

Patent-protected self-transfecting morpholino platform. The GMO-PMO chimera integrates guanidinium-functionalized morpholino residues into the PMO backbone — enabling direct cellular uptake without lipofection, electroporation, or viral delivery systems.

Self-Transfecting US Patents Direct Uptake

Patented GMO-PMO Chimera Technology

Self-transfecting morpholino chemistry · proprietary to GenElixir®

US 9,914,745 B2 US 12,012,427 B2 India 523395
GMO

GMO-PMO Chimera — Self-Transfecting

Cell-permeable antisense — no transfection needed

The GMO-PMO chimera integrates guanidinium-functionalized morpholino (GMO) units into a PMO backbone. The guanidinium groups facilitate direct cellular uptake, eliminating lipofection, electroporation, or viral delivery. In sequence notation, lowercase 'g' denotes guanidinium-modified residues.

No transfection reagents
In vivo & in vitro proven
Minimal doses required
Low toxicity profile
GMO · GILGMO401

Custom GMO-PMO Chimera (Antisense)

Proprietary self-transfecting morpholino oligomer. Cell-permeable without external agents. Lowercase 'g' denotes guanidinium-modified residues. US patent protected.
Purity ≥85% std · ≥95% avail.
Appearance White · Lyophilised
Storage −20°C / 2yr
Min. Order 250 nmol
Example Sequence
5′-GgGgAgTgAAAGACAGCAAATATCCTCAT-3′
GMO · GILGMO402

Control GMO-PMO Chimera (Scrambled)

Scrambled negative control with guanidinium-modified (g) residues at the same positions but no known mRNA target. Enables rigorous discrimination of sequence-specific vs cell-entry effects.
Purity ≥85% std · ≥95% avail.
Appearance White · Lyophilised
Storage −20°C / 2yr
Example Scrambled Control
5′-AgAgAgTgTAGGACACCAAATATTCTCAA-3′

GMO-PMO Chimera — Request a Quote

Custom sequence + scrambled control · 250 / 400 / 500 nmol · guanidinium modification included

Contact for Quote
Sequence & scale dependent
Traditional PMO
PMO + transfection reagent
GMO-PMO Chimera
Direct cellular uptake
↓ Continue to Category MM — Monomers ↓
MM

Morpholino Monomers

High-purity building blocks for in-house PMO synthesis. Four sub-families covering both protecting-group strategies (Trityl & Fmoc) and both activation states (standard & chlorophosphoramidate-activated). Ships within 2 business days (India). Contact us for a quote.

≥95–98% HPLC COA Available 2-Day Shipping 4 Sub-Families
CodeSub-FamilyCatalog RangeProtecting GroupActivationPurityStorageShelf Life
SMMTTrityl-Protected Standard MonomersGILSMMT001–004TritylStandard≥95%4°C2 years
SMMFFmoc-Protected Standard MonomersGILSMMF001–004FmocStandard≥95%4°C2 years
CMMTTrityl-Protected CPA Monomers (Activated)GILCMMT001–004TritylChlorophosphoramidate≥95%−20°C6 months
CMMFFmoc-Protected CPA Monomers (Activated)GILCMMF001–004FmocChlorophosphoramidate≥95–98%−20°C12 months
SMMT

Trityl-Protected Standard Morpholino Monomers

Six-membered morpholine ring bearing the nucleobase and N-trityl protecting group. Intermediate in multi-step PMO synthesis and building block for solution-phase assembly.

SMMT · GILSMMT001

Morpholino-A(Bz) [Trityl]

N6-Benzoyl-N-Trityl Morpholino Adenine
CAS 956139-16-5
MW 596.69
Formula C₃₆H₃₂N₆O₃
Purity ≥95% HPLC
Storage 4°C / 2yr
SMMT · GILSMMT002

Morpholino-C(Bz) [Trityl]

N-Trityl-Morpholino-N4-Bz-Cytosine
CAS 125515-31-3
MW 572.67
Formula C₃₅H₃₂N₄O₄
Purity ≥95% HPLC
Storage 4°C / 2yr
SMMT · GILSMMT003

Morpholino-5-Me-U [Trityl]

N-Trityl-Morpholino-5-Me-Uridine
CAS 914361-76-5
MW 483.57
Formula C₂₉H₂₉N₃O₄
Purity ≥95% HPLC
Storage 4°C / 2yr
SMMT · GILSMMT004

Morpholino-G(iBu) [Trityl]

N-Trityl-Morpholino-N2-iBu-Guanine
MW 578.67
Formula C₃₃H₃₄N₆O₄
Purity ≥95% HPLC
Storage 4°C / 2yr
SMMF

Fmoc-Protected Standard Morpholino Monomers

Morpholine ring with Fmoc (9-fluorenylmethyloxycarbonyl) protecting group. Used in Fmoc-based PMO synthesis protocols.

SMMF · GILSMMF001

Fmoc-Morpholino-A(Bz)

N6-Benzoyl-N-Fmoc Morpholino Adenine
MW 576.61
Formula C₃₂H₂₈N₆O₅
Purity ≥95% HPLC
Storage 4°C / 2yr
SMMF · GILSMMF002

Fmoc-Morpholino-C(Bz)

N-Fmoc-Morpholino-N4-Bz-Cytosine
MW 552.59
Formula C₃₁H₂₈N₄O₆
Purity ≥95% HPLC
Storage 4°C / 2yr
SMMF · GILSMMF003

Fmoc-Morpholino-5-Me-U

N-Fmoc-Morpholino-5-Me-Uridine
MW 463.49
Formula C₂₅H₂₅N₃O₆
Purity ≥95% HPLC
Storage 4°C / 2yr
SMMF · GILSMMF004

Fmoc-Morpholino-G(iBu)

N-Fmoc-Morpholino-N2-iBu-Guanine
MW 558.60
Formula C₂₉H₃₀N₆O₆
Purity ≥95% HPLC
Storage 4°C / 2yr
CMMT

Trityl-Protected Chlorophosphoramidate Monomers (Activated)

The 3′ chlorophosphoramidate group enables condensation during solid-phase PMO synthesis — direct building blocks consumed by automated PMO synthesizers. Storage at −20°C; 6-month shelf life.

CMMT · GILCMMT001

CPA-Morpholino-A(Bz) [Trityl]

Trityl-Chlorophosphoramidate Morpholino Adenine
MW 722.18
Formula C₃₈H₃₇ClN₇O₄P
Purity ≥95% HPLC
Storage −20°C / 6mo
CMMT · GILCMMT002

CPA-Morpholino-C(Bz) [Trityl]

Trityl-Chlorophosphoramidate Morpholino Cytosine
MW 698.16
Formula C₃₇H₃₇ClN₅O₅P
Purity ≥95% HPLC
Storage −20°C / 6mo
CMMT · GILCMMT003

CPA-Morpholino-5-Me-U [Trityl]

Trityl-Chlorophosphoramidate Morpholino Thymine
MW 609.06
Formula C₃₁H₃₄ClN₄O₅P
Purity ≥95% HPLC
Storage −20°C / 6mo
CMMT · GILCMMT004

CPA-Morpholino-G(iBu) [Trityl]

Trityl-Chlorophosphoramidate Morpholino Guanine
MW 704.16
Formula C₃₅H₃₉ClN₇O₅P
Purity ≥95% HPLC
Storage −20°C / 6mo
CMMF

Fmoc-Protected Chlorophosphoramidate Monomers (Activated — Fmoc Route)

Fmoc-variant of the activated CPA monomer set for Fmoc-based PMO synthesis protocols. Note the 12-month shelf life (longer than CMMT) and ≥95% purity specification (G base at ≥95%). Storage at −20°C.

CMMF · GILCMMF001

Fmoc-CPA-Morpholino-A(Bz)

Fmoc-Chlorophosphoramidate Morpholino Adenine
MW 702.10
Formula C₃₄H₃₃ClN₇O₆P
Purity ≥95% HPLC
Storage −20°C / 12mo
CMMF · GILCMMF002

Fmoc-CPA-Morpholino-C(Bz)

Fmoc-Chlorophosphoramidate Morpholino Cytosine
MW 678.08
Formula C₃₃H₃₃ClN₅O₇P
Purity ≥95% HPLC
Storage −20°C / 12mo
CMMF · GILCMMF003

Fmoc-CPA-Morpholino-5-Me-U

Fmoc-Chlorophosphoramidate Morpholino Thymine
MW 588.98
Formula C₂₇H₃₀ClN₄O₇P
Purity ≥95% HPLC
Storage −20°C / 12mo
CMMF · GILCMMF004

Fmoc-CPA-Morpholino-G(iBu)

Fmoc-Chlorophosphoramidate Morpholino Guanine
MW 684.09
Formula C₃₁H₃₅ClN₇O₇P
Purity ≥95% HPLC
Storage −20°C / 12mo

Category MM — Request a Quote

All 4 sub-families · minimum 1g order · ships within 2 business days (India) · contact us for current pricing

Call for Quote
Competitive pricing · Kg-scale available
The Science

Understanding Phosphorodiamidate
Morpholino Oligonucleotides

PMOs are next-generation antisense agents with an unmatched biological profile for gene silencing, splice correction, and therapeutic development.

What are PMOs?

Phosphorodiamidate Morpholino Oligonucleotides (PMOs) are synthetic, sequence-specific antisense agents. The morpholine ring replaces the natural ribose sugar, and phosphorodiamidate linkages replace the charged phosphodiester backbone. This non-ionic backbone is the key to their superior pharmacological profile.

PMOs of 20–30 nucleotides bind their complementary mRNA targets with high specificity, blocking translation or correcting aberrant splicing. They are nuclease-resistant, water-soluble, and exhibit minimal off-target and immune-stimulatory effects.

FDA-Validated Therapeutic Platform

The therapeutic power of PMOs is proven: four FDA-approved drugs for Duchenne Muscular Dystrophy are PMO-based, demonstrating the clinical viability of this chemistry in rare disease treatment.

Eteplirsen Golodirsen Casimersen Viltolarsen
// PMO Backbone Properties

Why Morpholino Chemistry Wins

Nuclease resistance✓ Excellent
Water solubility✓ High
Immune stimulation✓ Minimal
Off-target effects✓ Very low
Long-term activity✓ Sustained
Predictable targeting✓ Thermodynamic

Ref: Summerton JE. Current Topics in Medicinal Chemistry, 2007, 7, 651–660

PMO Advantages

Why Morpholino Oligonucleotides
Outperform Competing Technologies

Compared to siRNA, PNA, and S-DNA, morpholinos offer a uniquely favorable profile for research and therapeutic development.

Water Solubility

Fully water-soluble for easy formulation in aqueous buffers — no organic co-solvents needed.

Sequence Specificity

Binds target mRNA with high specificity via Watson-Crick base pairing, minimizing off-target effects.

No Antisense Artefacts

Minimal non-antisense activity — reduces experimental noise and improves result interpretability.

Non-Toxic Backbone

Excellent safety profile in cell culture and in vivo. Non-toxic to mammalian cells at effective doses.

Nuclease Stability

Highly resistant to nuclease degradation — active in complex biological matrices including serum.

Long-Term Activity

Sustained knockdown activity over extended periods — fewer dosing events for in vivo studies.

Clinical Efficacy

Validated in zebrafish, mouse, and human models. Clinically proven in four FDA-approved drugs.

Predictable Targeting

Thermodynamically predictable binding — enables rational sequence design with standard tools.

Four FDA-Approved PMO-Based Drugs

All approved for Duchenne Muscular Dystrophy — validating the clinical potential of PMO technology for rare and genetic diseases.

Eteplirsen — Exondys 51 Golodirsen — Vyondys 53 Casimersen — Amondys 45 Viltolarsen — Viltepso
Scientific Evidence

Peer-Reviewed Publications

The science behind GenElixir products is validated through peer-reviewed publications in leading journals including Nature Communications, Molecular Therapy, Journal of Organic Chemistry, and Bioconjugate Chemistry.

9
Publications
3
Platforms
7
Journals
2022–2026
Timespan
3
In Vivo Models
PMO

PMO Synthesis Technology

J Org
Chem

Synthesis of Phosphorodiamidate Morpholino Oligonucleotides Using Trityl and Fmoc Chemistry in an Automated Oligo SynthesizerAbOriginal AbstractPhosphorodiamidate morpholino oligonucleotides (PMOs) constitute 3 out of the 11 FDA-approved oligonucleotide-based drugs. PMOs can effectively silence disease-causing genes and modify splicing. However, PMO synthesis has remained challenging for a variety of reasons: inefficient deprotection and coupling methods and instability of monomers. Here, we report the development of a suitable combination of resin supports, deblocking and coupling reagents for synthesizing PMOs using either trityl or Fmoc-protected chlorophosphoramidate monomers. The protocol was successfully transferred into an automated DNA synthesizer to make several sequences of PMOs, demonstrating for the first time the adaptation of regular DNA/RNA synthesizer instrumentation for PMO assembly.

Kundu J, Ghosh A, Ghosh U, Das A, Nagar D, Pattanayak S, Ghose A, Sinha S J. Org. Chem. 2022 · 87(15):9466–78

Foundational paper demonstrating the first automated synthesis of PMOs using both Trityl and Fmoc-protected chlorophosphoramidate monomers on a standard DNA synthesizer. Established the chemistry underlying GenElixir's SMMT, SMMF, CMMT, and CMMF monomer product lines. Showed that ETT and iodine are suitable coupling reagents for efficient PMO assembly.

PMO Synthesis Trityl + Fmoc Chemistry Automated Synthesizer doi: 10.1021/acs.joc.2c00265
Chem
Rxiv

Solid Phase Synthesis of Casimersen and Its 3ʹ-End Modification for Therapeutic BenefitsAbOriginal AbstractThis work reports the complete solid-phase synthesis of Casimersen (Amondys 45), an FDA-approved 22-mer phosphorodiamidate morpholino oligonucleotide drug for Duchenne Muscular Dystrophy targeting exon 45. The study also introduces novel 3ʹ-end modifications designed to improve the therapeutic profile of Casimersen analogs, including conjugation handles and pharmacokinetic-enhancing groups.

Das A, Pratihar S, Nath Sharma S, Kundu J, Sinha S chemRxiv (Preprint) 2025

Reports the complete solid-phase synthesis of Casimersen (Amondys 45), one of four FDA-approved PMO drugs for Duchenne Muscular Dystrophy, along with novel 3′-end modifications designed to improve therapeutic properties. Demonstrates GenElixir's capability to synthesize clinically validated PMO sequences.

PMO Synthesis Casimersen / DMD 3′ End Modification
5′-PMO

5′-Functionalized PMO Platform

Bioconj
Chem

Synthesis of 5′-Thiol Functionalized Morpholino Oligonucleotide and Subsequent Conjugation with IGT to Improve Delivery and Antisense Efficacy In VitroAbOriginal AbstractThe synthesis of 5'-SH functionalized PMO is reported using a solid support synthesis protocol with an optimized cysteine-derived linker so that loading and coupling efficiency of morpholino monomers were effective enough to get a 25-mer 5'-SH functionalized PMO against human Nanog. This is the first report to illustrate that the IGT-PMO-mediated NANOG inhibition increases the therapeutic potential of taxol and induces G0-G1 arrest in cancer cells to prevent cancer progression.

Ghosh U, Gupta S, Sinha S Bioconjugate Chem. 2023 · 34(1):174–80

Introduces the 5′-thiol functionalized PMO synthesis using an optimized cysteine-derived linker — the chemistry behind GenElixir's TEG-Cysteine and DEG-Cysteine end modifications. The thiol handle enabled conjugation with an internal guanidinium transporter (IGT) peptide, significantly improving cellular delivery and NANOG knockdown in MCF7 breast cancer cells.

5′-Functionalized PMO Thiol-Maleimide MCF7 Cells IGT Conjugation
Mol
Pharm

Synthesis of Self-Permeable Antisense PMO Using C5-Guanidino-Functionalized Pyrimidines at the 5′-End Enables Sox2 Downregulation in Triple Negative Breast Cancer CellsAbOriginal AbstractPMO-based delivery agents having 3 or 4 guanidinium groups at the C5 position of the nucleobases of cytosine and uracil have been explored, which can be assimilated within the desired stretch of the antisense oligonucleotide. These self-permeable antisense PMOs enabled efficient Sox2 downregulation in the triple-negative breast cancer cell line MDA-MB-231, demonstrating a novel approach to solving the cell delivery problem of morpholino oligonucleotides.

Das A, Gupta S, Shaw P, Sinha S Mol. Pharmaceutics 2024 · 21(3):1256–71

Describes a novel class of self-permeable PMO carrying C5-guanidino-functionalized pyrimidine bases at the 5′ terminus — an alternative GMO-PMO architecture where the guanidinium groups are attached to the nucleobases rather than the backbone. Successfully downregulated Sox2 in the aggressive triple-negative breast cancer cell line MDA-MB-231.

5′-Functionalized PMO Base-linked Guanidinium MDA-MB-231 TNBC Sox2 Knockdown
GMO

GMO-PMO Chimera Platform

Mol Ther
Nucl Acids

Self-Transfecting GMO-PMO Chimera Targeting Nanog Enables Gene Silencing In Vitro and Suppresses Tumor Growth in 4T1 Allografts in MouseAbOriginal AbstractPhosphorodiamidate morpholino oligonucleotide (PMO)-based antisense reagents cannot enter cells without the help of a delivery technique, which limits their clinical applications. To overcome this problem, self-transfecting guanidinium-linked morpholino (GMO)-PMO chimeras have been explored as antisense agents. GMO facilitates cellular internalization and participates in Watson-Crick base pairing. Targeting NANOG in MCF7 cells resulted in decline of the whole epithelial to mesenchymal transition (EMT) and stemness pathway. GMO-PMO-mediated knockdown of no tail gene resulted in desired phenotypes in zebrafish. In BALB/c mice, 4T1 allografts were found to regress via intra-tumoral administration of NANOG GMO-PMO antisense oligonucleotides.

Das U, Kundu J, Shaw P, Bose C, Ghosh A, Gupta S, Sarkar S, Bhadra J, Sinha S Mol. Ther. Nucleic Acids 2023 · 32:203–228

The landmark GMO-PMO chimera publication and GenElixir's core patent validation study. Demonstrated that GMO-PMO chimeras targeting NANOG enter cells autonomously, silence the EMT and stemness pathway in MCF7 cells, produce expected phenotypes in zebrafish even after 16-cell stage delivery, and suppress 4T1 mammary carcinoma allografts in BALB/c mice with restoration of organ histopathology.

GMO-PMO Chimera Open Access · GenElixir Supported MCF7 · Zebrafish · BALB/c Mice NANOG / EMT / Stemness
bio
Rxiv

Cell-Permeable Morpholino Inhibits Programmed Death-Ligand 1 at mRNA Level and Potentiates Antitumor Immunity in Breast CancerAbOriginal AbstractThis study demonstrates that a cell-permeable GMO-PMO chimera targeting PD-L1 mRNA can inhibit immune checkpoint expression in multiple breast cancer cell lines (MDA-MB-231, MDA-MB-468) and potentiate antitumor T-cell immunity using Jurkat E6.1 lymphoblasts. In vivo efficacy was confirmed in BALB/c albino mice, positioning GMO-PMO chimera technology as a potential alternative to anti-PD-L1 antibody-based immunotherapy for breast cancer.

Sarkar S, Ghosh U, Pratihar S, Sinha S bioRxiv (Preprint) 2026

Extends GMO-PMO chimera technology into immuno-oncology. The chimera targeting PD-L1 mRNA inhibits immune checkpoint expression in multiple breast cancer cell lines (MDA-MB-231, MDA-MB-468) and potentiates antitumor T-cell immunity using Jurkat E6.1 lymphoblasts. In vivo efficacy confirmed in BALB/c mice — positioning GMO-PMO as a potential alternative to anti-PD-L1 antibody immunotherapy.

GMO-PMO Chimera PD-L1 / Immunotherapy TNBC · Jurkat T-Cells · Mice
Front Cell
Infect

AUF-1 Knockdown in Mice Undermines Gut Microbial Butyrate-Driven Hypocholesterolemia Through AUF-1–Dicer-1–mir-122 HierarchyAbOriginal AbstractAUF-1 knockdown using GMO-PMO chimera in mice revealed that AUF-1 is required for gut microbial butyrate-driven hypocholesterolemia through the AUF-1-Dicer-1-miR-122 regulatory hierarchy. This study validates the in vivo gene silencing capability of GMO-PMO chimera technology in a non-oncology context — specifically gut microbiome and cholesterol metabolism research.

Das O, Kundu J, Ghosh A, Gautam A, Ghosh S, Chakraborty M, Masid A, Gauri SS, Mitra D, Dutta M, Mukherjee B, Sinha S, Bhaumik M Front. Cell. Infect. Microbiol. 2022 · 12:1011386

Independent validation of GMO-PMO chimera technology in a gut microbiome and cholesterol metabolism context. GMO-PMO was used to knock down AUF-1 in mice, revealing that AUF-1 is required for butyrate-driven cholesterol reduction via the Dicer-1/miR-122 axis. Demonstrates the chimera's in vivo delivery and gene silencing in a non-oncology disease model.

GMO-PMO Chimera Mice · In Vivo AUF-1 / Cholesterol / Microbiome
Athero
sclerosis

Hepatic GSTM3 Deficiency Accelerates Atherosclerosis Through Redox-Driven Mitochondrial Dysfunction and Necroinflammation in Apoe⁻/⁻ MiceAbOriginal AbstractUsing GMO-PMO chimera as the gene silencing tool, this study demonstrated that hepatic GSTM3 deficiency in Apoe-knockout mice accelerates atherosclerotic plaque formation through redox-driven mitochondrial dysfunction and necroinflammation. The GMO-PMO chimera enabled efficient hepatic gene knockdown in the cardiovascular disease mouse model.

Roy T, Ray AG, Pratihar S, Sarkar S, Sinha S, Alam MJ, Mabalirajan U, Bandyopadhyay A Atherosclerosis 2026 · p.120764

GMO-PMO chimera used as the gene silencing tool in an atherosclerosis study. Hepatic GSTM3 knockdown in Apoe-knockout mice demonstrated that GSTM3 deficiency accelerates plaque formation through mitochondrial redox dysfunction and necroinflammation — validating the chimera's efficacy in cardiovascular disease research models.

GMO-PMO Chimera Apoe⁻/⁻ Mice · In Vivo Atherosclerosis / GSTM3
Nature
Comms

Optochemical Control over mRNA Translation by Photocaged Phosphorodiamidate Morpholino Oligonucleotides In VivoAbOriginal AbstractWe developed an efficient, robust, and broadly applicable system for light-induced protein translation to control the production of proteins of interest and study their function. The method is based on the displacement of a single type of antisense morpholino from RNA by the uncaged guanidinium-linked morpholino (GMO)-phosphorodiamidate morpholino oligonucleotide (PMO) chimera upon UV irradiation. The GMO-PMO chimera designed here is cell-permeable and the GMO part can be produced employing a mercury-free approach compatible with the synthesis on solid support. We demonstrate the function of this optochemical approach in live embryos by inducing, at desired times and locations, the expression of proteins that label specific cells, ablate tissue regions, and affect embryonic development.

Tarbashevich K, Ghosh A, Das A, Kuilya D, Sharma SN, Sinha S, Raz E Nature Communications 2025 · 16:3614

Highest-impact publication. Collaboration with Prof. Erez Raz (University of Münster / Max Planck). Developed a light-activated system where UV irradiation uncages a GMO-PMO chimera that displaces an antisense morpholino from target mRNA, enabling spatiotemporal control of protein expression in live zebrafish embryos. The cell-permeable GMO-PMO chimera was produced using a mercury-free solid-phase approach.

GMO-PMO Chimera Nature Communications Zebrafish · In Vivo Photocaged / Optochemical Münster / Max Planck
Applications

Research Applications for GenElixir Morpholinos

Phosphorodiamidate Morpholino Oligonucleotides and GMO-PMO chimeras enable a wide range of research workflows. Below are the most common research applications and which GenElixir products are best suited to each.

// Gene Silencing

Knockdown of mRNA Translation

PMOs block the AUG start codon or 5′UTR of target mRNA to prevent ribosomal binding and translation, achieving selective knockdown of target gene expression without RNase H or RISC machinery.

→ Recommended: Custom PMO (PMO · GILPMO301-T)
// Splice Correction

Exon Skipping / Inclusion

PMOs targeting splice donor or acceptor sites can force exon skipping or inclusion — the mechanism behind FDA-approved DMD drugs eteplirsen, golodirsen, casimersen, and viltolarsen.

→ Recommended: Custom PMO with sequence-optimized targeting
// Zebrafish Embryology

Developmental Biology Knockdown

The gold-standard reagent for zebrafish gene knockdown studies. PMOs are microinjected into 1–4 cell stage embryos for stable, predictable phenotypic analysis through early development.

→ Recommended: Standard 25-mer Custom PMO
// Cell-Permeable Antisense

In Vitro Studies Without Transfection

Patented GMO-PMO chimera enters mammalian cells autonomously — eliminating lipofection, electroporation, and viral vectors. Reduces toxicity and dosing complexity compared to Vivo-Morpholinos.

→ Recommended: Custom GMO-PMO Chimera (GMO · GILGMO401)
// Fluorescent Tracking

Intracellular Localization Studies

BODIPY-labelled PMOs enable real-time fluorescence imaging of oligo uptake and subcellular distribution (λex 498 nm, ε = 79,000 cm⁻¹ M⁻¹).

→ Recommended: 3′-BODIPY end modification
// Bioconjugate Chemistry

Click & Maleimide Coupling

Alkyne-Serine handles enable CuAAC/SPAAC click conjugation with azide-bearing payloads. TEG/DEG-Cysteine handles enable thiol-maleimide conjugation for antibody-PMO and polymer-PMO constructs.

→ Recommended: 3′ or 5′ Alkyne-Serine / TEG-Cysteine mods
// In-House PMO Synthesis

Building Blocks for Synthesizers

Trityl-protected (MM1) and chlorophosphoramidate (MM2) morpholino monomers for all four nucleobases enable in-house solid-phase PMO assembly on standard oligonucleotide synthesizers.

→ Recommended: Category MM monomers (1g+ minimum)
// Rare Disease Research

DMD & Genetic Disorder Pipelines

PMOs are the dominant chemistry class for Duchenne Muscular Dystrophy research and other rare diseases involving aberrant splicing or undesired protein expression — backed by four FDA approvals.

→ Recommended: Custom sequence PMO + scrambled control
Who We Serve

Trusted by the Global Scientific Community

GenElixir supplies morpholino reagents to four primary customer segments across India and worldwide — from individual academic labs to large pharmaceutical R&D pipelines.

// 01

Universities & Academic Research

Principal investigators in molecular biology, developmental biology, gene therapy, and rare disease research. Special academic pricing for funded research projects.

IISc · IITs · IACS Kolkata · CCMB · AIIMS · NBRC · JNCASR · Johns Hopkins · NIPER · GITAM
// 02

Pharmaceutical Companies

Antisense and gene therapy program teams sourcing PMO reagents and custom oligomers for preclinical development of rare disease and splice-correction therapeutics.

Biotech R&D · Antisense programs · Gene therapy pipelines · Rare disease drug discovery
// 03

CROs & CDMOs

Contract research and contract manufacturing organizations expanding into oligonucleotide services — sourcing morpholino monomers, custom oligos, and gram-scale PMO supply.

Oligo CDMOs · Custom synthesis CROs · Specialty chemistry contract labs
// 04

Government & Institutional Research

Publicly funded research labs working on genetic disorders, DMD, and rare disease therapeutics. Procurement support for DBT, CSIR, and ICMR-funded projects.

DBT · CSIR · ICMR · DST · UMMID program · Make in India biotech grants
Market Position

GenElixir vs. Global Suppliers

India's only PMO manufacturer delivers capabilities previously available only from US and China — at substantially better economics and timelines.

Capability
GenElixir®
Gene Tools (US) Hongene (CN/US) BOC Sciences (US) Biosynth (CH) WuXi AppTec (CN)
India-based manufacturing✓ Only one— None— None— None— None— None
Cost vs US/EU baseline✓ 40–60% lowerBase price~ Moderate~ ModerateBase price~ Moderate
GMO-PMO chimera (patented)✓ Proprietary— No— No— No— No— No
Custom PMO oligomers
Morpholino monomers✓ Full MM1+MM2~ Limited~ Limited~ Via CDMO
India delivery speed✓ 5 business days1–2 weeks2–4 weeks2–4 weeks2–3 weeks2–4 weeks
End mods (BODIPY, Click, TEG)✓ Full range✓ Vivo-Morpholinos~ Partial~ Partial~ Partial✓ CDMO
Gram-scale CDMO✓ via partnership 2027~ Limited— No~ Limited✓ GMP
In-house HPLC QC
Self-transfecting tech✓ GMO-PMO chimeraVivo (dendrimer)— No— No— No— No

Comparison data compiled from publicly available product catalogs and pricing references as of June 2026. Sources: gene-tools.com, hongene.com, bocsci.com, biosynth.com, wuxiapptec.com. Additional PMO market participants include Sarepta Therapeutics (PMO/PPMO therapeutic drugs only — not reagent supplier), Amerigo Scientific (US, limited monomer catalog), Asymchem (China, contract manufacturing), Nitto Denko Avecia (US, GMP oligo CDMO), and The Morpholino Group / IACS Kolkata (academic R&D laboratory, not commercial supplier).

Recognition

Recognized at the Highest Levels

Our pioneering work in PMO-based therapeutics has attracted recognition from government, industry, and the academic community.

Government of India
Ministerial Recognition

Dept. of Science & Technology

Union Minister Dr. Jitendra Singh Visits GenElixir

Dr. Jitendra Singh, Union Minister for Department of Science and Technology, Government of India, visited the GenElixir booth during his official visit to Kolkata — recognizing GenElixir's pioneering role in India's antisense therapeutics landscape.

Nucleic Acid Therapeutics
Meeting 2025

JNCASR · Bengaluru

Presented at JNCASR Nucleic Acid Therapeutics Meeting

GenElixir presented our GMO-PMO chimera technology at the 2025 Nucleic Acid Therapeutics Meeting at JNCASR Bengaluru — engaging directly with India's leading nucleic acid research community.

// Our Mission
"We provide custom-designed antisense PMOs, cell-permeable GMO-PMO chimeras, Morpholino monomers, linkers, loading monomers, and various other functionalized monomers — enabling the manufacturing and discovery of antisense-based medicines."
Academic & Research Partners
JNCASR Johns Hopkins University NIPER Kolkata GITAM University IACS
Ordering

Simple, Straightforward Ordering

No minimum contract, no platform lock-in. Order what you need when you need it, with responsive scientific support throughout.

MM

Category MM — Morpholino Monomers

Min. 1g · Ships 2 days · Call for quote

  1. 1

    Select your catalog number (GILSMMT/SMMF/CMMT/CMMF 001–004) from the product table

  2. 2

    Specify quantity in grams (minimum 1 gram per order)

  3. 3

    Indicate if HPLC certificate of analysis is required (additional cost)

  4. 4

    Send your order to sales@genelixir.com — our team responds within 1 business day. Monomers ship within 2 business days (India)

MO

Category MO — Custom Oligomers

250 nmol minimum · Pricing on inquiry

  1. 1

    Specify product type: Standard PMO or GMO-PMO Chimera

  2. 2

    Provide your 5′→3′ nucleotide sequence (lowercase 'g' for GMO residues)

  3. 3

    Select quantity: 250 / 400 / 500 nmol — or specify larger amount

  4. 4

    Specify end modifications (BODIPY, Click, TEG/DEG spacers) if required

  5. 5

    Email sales@genelixir.com — formal quotation within 2 business days

Questions? Talk to a Scientist

Our chemistry team is available for pre-order technical consultation — sequence design, modification strategy, experimental planning, and scale-up discussion.

India
+91 897 773 4216
USA
+1 856 975 0444
Common Questions

Answers to Common Questions About PMOs & GenElixir

Direct answers to the questions our customers, AI assistants, and procurement teams most often ask about Phosphorodiamidate Morpholino Oligonucleotides, GMO-PMO chimera technology, and ordering from GenElixir.

Q01What is a Phosphorodiamidate Morpholino Oligonucleotide (PMO)?
A Phosphorodiamidate Morpholino Oligonucleotide (PMO) is a synthetic antisense oligonucleotide in which the natural ribose sugar is replaced with a six-membered morpholine ring, and the charged phosphodiester backbone is replaced with non-ionic phosphorodiamidate linkages. PMOs of 20–30 nucleotides bind complementary mRNA with high sequence specificity for gene silencing (translational blockade) or splice correction (exon skipping/inclusion). They are nuclease-resistant, fully water-soluble, and exhibit minimal off-target and immune-stimulatory effects. Four FDA-approved drugs for Duchenne Muscular Dystrophy — eteplirsen, golodirsen, viltolarsen, and casimersen — are PMO-based.
Q02Where can I buy custom PMOs in India?
GenElixir® in Visakhapatnam, Andhra Pradesh is India's only dedicated manufacturer of custom Phosphorodiamidate Morpholino Oligonucleotides (PMOs). Founded in 2019, GenElixir synthesizes custom-sequenced PMOs, GMO-PMO chimeras, and morpholino monomers (Trityl-protected and Fmoc-protected, in both standard and Chlorophosphoramidate-activated forms) for the full range of antisense research needs. Orders ship within India in 5 business days at 40–60% lower cost than US or EU suppliers. Contact sales@genelixir.com or call +91 897 773 4216.
Q03What is a GMO-PMO chimera?
A GMO-PMO chimera is a patented self-transfecting antisense oligonucleotide developed by GenElixir®. It integrates guanidinium-functionalized morpholino (GMO) units into a standard PMO backbone, enabling the molecule to enter mammalian cells without transfection reagents, viral vectors, or electroporation. The technology is protected by US Patents 9,914,745 B2 and 12,012,427 B2, plus India Patent 523395. It is positioned as an alternative to Gene Tools' Vivo-Morpholinos with reduced toxicity, no excess guanidinium, and lower effective dosing.
Q04How does GenElixir compare to Gene Tools LLC?
Gene Tools LLC (Philomath, Oregon, USA) is the historical near-monopoly supplier of custom PMOs for research. GenElixir® offers comparable PMO chemistry plus a proprietary self-transfecting GMO-PMO chimera (US-patented) that Gene Tools does not have. Key differences:

Cost: GenElixir is 40–60% lower than Gene Tools
Speed: 5-day shipping within India vs. 1–2 weeks from Oregon
Monomers: GenElixir manufactures full A/C/T/G ranges in four sub-families: SMMT (Trityl standard), SMMF (Fmoc standard), CMMT (Trityl CPA-activated), and CMMF (Fmoc CPA-activated); Gene Tools supplies only limited monomers
Self-transfecting tech: Patent-protected GMO-PMO chimera vs. Gene Tools' Vivo-Morpholinos (dendrimer-conjugated)
Q05What is the difference between a PMO and a GMO-PMO chimera?
A standard PMO is a non-ionic antisense oligomer that typically requires external transfection reagents, electroporation, or viral vectors to enter mammalian cells efficiently. A GMO-PMO chimera incorporates guanidinium-functionalized morpholino residues that confer cell-permeability — the chimera enters cells autonomously without transfection agents, with minimal toxicity and at lower effective doses. The GMO-PMO chimera is GenElixir's patent-protected technology and is sequence-customized to the target mRNA just like a standard PMO.
Q06What end modifications are available on PMOs and GMO-PMO chimeras?
GenElixir offers five end modifications at either the 3′ or 5′ terminus of PMO and GMO-PMO chimera oligomers:

1. BODIPY — fluorescent tracker for intracellular localization (λex 498 nm, ε = 79,000 cm⁻¹ M⁻¹)
2. Alkyne-Serine — click chemistry handle for CuAAC or SPAAC conjugation with azide-bearing payloads
3. TEG-Cysteine — Michael addition (thiol-maleimide) handle with triethylene glycol spacer for aqueous solubility
4. DEG-Cysteine — compact thiol-maleimide handle with diethylene glycol spacer
5. Triethylene Glycol — neutral PEG-like spacer that improves solubility and reduces nonspecific binding
Q07What is the minimum order quantity?
Custom oligomers (Category MO): 250 nmol minimum, with 400 nmol and 500 nmol standard scales. Larger quantities are available on inquiry. Gram-scale production is available from 2027 via industry partnership.

Morpholino monomers (Category MM): 1 gram minimum. Contact us for current pricing. Kilogram-scale supply is available from Q1 2027.
Q08Which FDA-approved drugs use PMO chemistry?
Four FDA-approved drugs use Phosphorodiamidate Morpholino Oligonucleotide chemistry, all developed by Sarepta Therapeutics and Nippon Shinyaku for Duchenne Muscular Dystrophy (DMD):

Eteplirsen (Exondys 51) — exon 51 skipping
Golodirsen (Vyondys 53) — exon 53 skipping
Casimersen (Amondys 45) — exon 45 skipping
Viltolarsen (Viltepso) — exon 53 skipping

These approvals validate the clinical safety and efficacy of PMO chemistry for rare and genetic diseases.
Q09Does GenElixir provide certificates of analysis?
Yes. GenElixir provides HPLC-purity certificates of analysis (CoA) for all monomer batches, certifying ≥95% purity. CoAs are available for an additional fee and are typically delivered with the shipment. All in-house QC is performed at the Visakhapatnam manufacturing facility using standardized HPLC methods. Custom oligomer batches include synthesis confirmation and a quality summary.
Q10How fast does GenElixir deliver?
Within India: Morpholino monomer orders ship in 5 business days — dramatically faster than the 1–2 weeks typical of US-based suppliers (Gene Tools) or 2–4 weeks from China-based suppliers (Hongene, WuXi).

International: US/EU shipments are handled via our New Jersey office with appropriate transit timelines and documentation.

Custom oligomers: Synthesis time depends on sequence length, scale, and modifications, and is confirmed at the time of quotation.
Q11Are PMOs water-soluble and non-toxic?
Yes — these are two of the defining advantages of PMO chemistry. PMOs are fully water-soluble and require no organic co-solvents for formulation. The phosphorodiamidate backbone is non-ionic, which means PMOs exhibit minimal immune stimulation, very low off-target effects, and are non-toxic to mammalian cells at effective doses. These properties underpin their use in four FDA-approved therapeutic drugs.
Q12How do I order a custom PMO from GenElixir?
Custom PMO and GMO-PMO orders take 5 steps:

1. Specify product type: Standard PMO or GMO-PMO Chimera
2. Provide your 5′→3′ nucleotide sequence (use lowercase 'g' for guanidinium-modified residues in GMO chimeras)
3. Select scale: 250 / 400 / 500 nmol (or specify larger)
4. Specify end modifications (BODIPY, Click handles, TEG/DEG spacers) if required
5. Email sales@genelixir.com — formal quotation within 2 business days

Let's Collaborate for a Healthier Future

Our team is ready to support your research with high-quality products, technical expertise, and reliable service you can count on.

Email
sales@genelixir.com
Website
www.genelixir.com
India Office
Plot 9, NH-16
Marikivalasa
Visakhapatnam, AP 530048
USA Office
154 Cooper Rd, Suite 202
West Berlin, NJ 08091
Trusted Quality
Rigorous standards. Reliable results.
Scientific Partnership
Collaborative support at every step.
Global Reach
Serving researchers worldwide.
Sustainable Future
Responsible innovation for a better tomorrow.
Original Abstract